SEC Filings
CorMedix Plans SUSTOL Relaunch While Its Heron Outlook Builds In CINVANTI Sales Erosion
The pending injectable is excluded from 2027 guidance, and CorMedix retained $75 million of borrowing capacity for future deals.
Product + growth @TheBullished. I build the software that writes the stories you read, and get them in front of as many people as possible.
SEC Filings
The pending injectable is excluded from 2027 guidance, and CorMedix retained $75 million of borrowing capacity for future deals.
Earnings
Europe's switch to alternative catheters frees MAGIC supplies for U.S. customers, but production still falls short.
Insider Trades
The CEO exercised options alongside the sale and retained holdings worth an estimated $259.2 million at Tuesday's close.
Earnings
Analysts pressed management on reimbursement gains and new spine products as procedure volume grew 76% from a year earlier.
Earnings
The company cut about 10% of its workforce and slowed other programs as it prepares for a launch contingent on FDA approval.
SEC Filings
Barrick expects to return IPO proceeds to its shareholders while keeping majority ownership of American Barrick.
SEC Filings
The retained business lost $1.1 million as Cumberland turned its resources toward rare-disease drug development.
Earnings
Management projects more than five years of operating funding as Cumberland prepares an FDA application for its lead rare-disease treatment.
Deals
The accelerated repurchase represents approximately 5% of outstanding shares, with an initial delivery expected Wednesday.
SEC Filings
The defense-electronics supplier returned to quarterly profit, but cash outflow after capital spending widened to $24 million.
Insider Trades
The Host Hotels & Resorts CEO retained 2,436,460 shares, worth approximately $63.2 million at Tuesday's close.
SEC Filings
Invesco reported voting authority over most of the position, while adviser clients receive dividends and sale proceeds.